Although it has not been confirmed whether the spleen acts as a reservoir of MDSC in humans, the results of the current study strongly indicate that the efficacy of combining spleen-targeting therapies with platinum-based chemotherapy is worth investigating in future clinical trials involving G-CSF-producing cervical cancer patients. This evidence concerns the gene CSF3 and cervical cancer.